3种单克隆抗体治疗炎症性肠病的临床综合评价OA

AIM To carry out the comprehensive evaluation of 3 monoclonal antibodies in the treatment of inflammatory bowel disease from different dimensions,providing a basis for clinical rational drug use.METHODS According to the Guidelines for the management of comprehensive clinical evaluation of pharmaceuticals(2021 trial edition),evidence-based medicine research and quantitative data analysis were mainly used to comprehensively evaluate 6 dimensions:safety,effectiveness,economics,accessibility,innovation,suitability,and accessibility of vedolizumab,infliximab and adalimumab.RESULTS In terms of safety,the pre-market studies of adalimumab showed better performance,and the post-market studies of vedolizumab showed milder adverse reactions.In terms of effectiveness,infliximab was more suitable for the induction period of Crohn's disease and ulcerative colitis.Vedolizumab was more suitable for the treatment of stable ulcerative colitis and for ulcerative colitis after the failure of infliximab treatment.Adalimumab was more suitable for the treatment of Crohn's disease after the failure of infliximab treatment.In terms of cost-effectiveness,there was a significant difference in the results from different countries.Vedolizumab had a better performance in terms of innovation.In terms of suitability,adalimumab had more advantages.In terms of accessibility,the price levels of all three drugs in our country were below international standards.The availability of infliximab was more advantageous,while the affordability of adalimumab and vedolizumab was better for urban residents.CONCLUSION Each of the 3 monoclonal antibodies has its advantages in treating inflammatory bowel disease.A comparative evaluation of their effectiveness and cost-effectiveness in the Chinese population is necessary to inform clinical practice and assist medical insurance departments in making relevant decisions regarding rational drug use.